Novartis next to bow out of antibiotics

12 July 2018

With antimicrobial resistance (AMR) on the rise and health authorities and foundations around the world crying out for new antibiotics, Novartis (NOVN: VX) has become the latest big pharma company to exit the space.

Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) and USA-based Eli Lilly (NYSE: LLY) are among those that have ceased research in the field in recent years, and the Swiss giant has now joined them.

"While the science for these programs is compelling, we have decided to prioritize our resources in other areas"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK